logo
logo
OFIX stock ticker logo

Orthofix Medical Inc.

NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
板块: Healthcare
行业: Medical - Devices
上市日期: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
联系方式
3451 Plano Parkway, Lewisville, TX, 75056, United States
214-937-2000
www.orthofix.com
市值
$509.65M
市盈率 (TTM)
-5.6
29.5
股息率
--
52周最高
$17.60
52周最低
$10.24
52周范围
36%
排名38Top 36.9%
4.3
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
一般 • 4.3 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025

财务仪表盘

Q4 2025 数据

营业收入

$219.91M+0.00%
近4季度走势

每股收益

-$0.06+0.00%
近4季度走势

自由现金流

$7.12M+0.00%
近4季度走势

2025 Annual 财报亮点

核心亮点

Net Sales Growth Achieved Total net sales reached $822.3M, reporting 2.9% growth; constant currency growth was 2.4% for the year.
Gross Margin Expansion Gross Margin improved 0.5 points to 68.8%; Net Loss narrowed by $33.8M compared to the prior year results.
Limb Reconstruction Sales Rise Global Limb Reconstruction sales increased 8.4% reported to $134.7M; U.S. growth led at 15.8% driven by investments.
R&D Spending Reduced Research and development expense decreased 10.6% to $65.8M following strategic discontinuation of M6 product lines.

关注风险

Healthcare Industry Consolidation Industry consolidation pressures pricing; GPOs/IDNs may exclude suppliers, materially affecting profitability and market access.
Integration of SeaSpine Merger Continued SeaSpine integration poses risk; failure to achieve intended synergies may adversely affect operating efficiencies and cost savings goals.
Pending Litigation Exposure Multiple litigation and arbitration matters pending, including former executives; accrual of $18.3M reflects ongoing financial uncertainty.
Regulatory Compliance Costs Extensive global regulation, especially E.U. MDR, requires significant ongoing costs to maintain compliance and market access.

前瞻展望

Focus on Profitable Growth Discontinuing M6 product lines to allocate resources toward more profitable growth opportunities across Global Spine segment.
Digital Platform Leverage Limb Reconstruction strategy emphasizes leveraging OrthoNext digital platform for planning and improving surgical outcomes.
Spine Technology Development Future growth driven by internally developed technologies and external acquisitions, focusing on cervical and thoracolumbar anatomy.
Liquidity Management Intend to retain consolidated earnings to finance continued growth; currently compliant with $15.0M unrestricted cash covenant.

同行对比

营业收入 (TTM)

VREX stock ticker logoVREX
$854.40M
+4.1%
OFIX stock ticker logoOFIX
$822.31M
+2.9%
AVNS stock ticker logoAVNS
$701.20M
+1.9%

毛利率 (最新季度)

ABSI stock ticker logoABSI
100.0%
+197.2pp
KALV stock ticker logoKALV
91.0%
+0.0pp
LAB stock ticker logoLAB
83.5%
-3.2pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
MLTX$1.29B-5.1-67.1%17.8%
SVRA$1.14B-10.5-86.6%21.2%
BFLY$1.02B-13.2-35.3%6.0%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
4.3%
温和增长
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
75%
现金流波动较大

深度研究

下次财报:2026年5月4日
|
每股收益:-
|
营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据